Orlistat is a weight management medication containing Orlistat, a gastrointestinal lipase inhibitor designed to prevent dietary fat absorption and promote weight loss. It belongs to a class of drugs that block pancreatic and intestinal lipases, reducing calorie intake from fats. Orlistat is primarily prescribed for obese patients or those overweight with comorbidities like diabetes or hypertension, alongside diet and exercise, to achieve significant and sustained weight reduction.

Orlistat offers a targeted approach to obesity treatment through its selective inhibition of gastric and pancreatic lipases. Unlike systemic appetite suppressants, Orlistat binds covalently to the serine residue on lipase enzymes within the intestinal lumen, preventing the hydrolysis of triglycerides into absorbable free fatty acids and monoacylglycerols. Approximately 30% of consumed dietary fat is left unabsorbed and excreted in faeces, leading to a caloric deficit without affecting carbohydrate or protein metabolism. This localised action minimises systemic exposure while effectively promoting fat malabsorption. For patients struggling with caloric control, it reduces body weight by 5-10% over a year when combined with lifestyle changes, lowers HbA1c in diabetics, and improves lipid profiles.

Clinical trials confirm benefits in preventing weight regain post-loss. Pharmacokinetics show minimal absorption (less than 1%), with faecal excretion of the parent drug and metabolites; it has few drug interactions beyond fat-soluble vitamins, requiring supplementation with multivitamins. Uses of Orlistat

Chronic Weight Management: Long-term treatment of obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with risk factors.

Obesity-Related Comorbidities: Adjunct in type 2 diabetes, hypertension, or dyslipidemia.

Weight Loss Maintenance: Preventing regain after initial diet-induced loss.

Prediabetes Prevention: Reducing progression to type 2 diabetes in at-risk individuals.

• Selective Fat Blockade: Inhibits 25-30% of dietary fat absorption, creating a caloric deficit without hunger.

• Sustained Weight Loss: Achieves 8-10% body weight reduction over 1-2 years, superior to placebo.

• Metabolic Improvements: Lowers LDL cholesterol, blood pressure, and glycemic control in diabetics.

• Cardiovascular Risk Reduction: Decreases the incidence of type 2 diabetes and improves lipid parameters.

• No Central Nervous Effects: Avoids stimulant side effects, suitable for long-term use.

• Supports Compliance: Visible faecal fat signals efficacy, reinforcing dietary fat moderation.

While Orlistat is highly effective, gastrointestinal side effects occur due to unabsorbed fat. Most are mild and decrease over time with a low-fat diet.

Common Side Effects

• Oily spotting

• Fatty or oily stools

• Increased defecation urgency

• Flatulence with discharge

• Steatorrhea

Uncommon Side Effects

• Abdominal pain

• Rectal discomfort

• Bloating

• Mild liver enzyme changes

Serious Side Effects (Requires Immediate Clinical Intervention)

• Severe allergic reaction: Rash, itching, swelling, or anaphylaxis.

• Acute kidney injury: Reduced urine output or flank pain (rare oxalate nephropathy).

• Cholelithiasis: Gallbladder pain from rapid weight loss.

• Severe GI distress: Persistent diarrhoea leading to dehydration or electrolyte imbalance.

Orlistat is usually taken three times daily, with each main meal containing fat (up to 1 hour after eating). The medication should be swallowed whole with a glass of water; it can be taken during a meal or shortly after. For best results, follow a reduced-calorie, low-fat diet (less than 30% calories from fat) and take a daily multivitamin at bedtime, at least 2 hours away from doses, to replace fat-soluble vitamins. Do not take if the meal has no fat or is skipped. Consistency matters: regular use with lifestyle changes maximises weight loss benefits.

The mechanism of Orlistat centres on inhibiting gastric and pancreatic lipases in the gut. Orlistat binds covalently to the active serine site on these enzymes, preventing the breakdown of dietary triglycerides into absorbable free fatty acids and monoglycerides. About 25-30% of ingested fat remains unabsorbed, passes through the intestines, and is excreted in faeces, creating a caloric deficit specifically from fat without impacting carbs or proteins. This localised GI action promotes gradual weight loss while minimising systemic effects.

• Manage GI Side Effects: Oily spotting and faecal urgency often improve within weeks; stick to a low-fat diet (<30% calories from fat) to minimise them. Use over-the-counter remedies like loperamide sparingly for loose stools if needed, but consult your doctor first.

• Monitor Vitamin Levels: Take a daily multivitamin containing fat-soluble vitamins (A, D, E, K) at least 2 hours before or after doses, as Orlistat reduces their absorption.

• Follow a low-fat diet: Limit fat intake per meal to 15g or less; high-fat meals worsen side effects and reduce efficacy. Track diet to support weight loss goals.

• Regular Check-Ups: Get liver function tests and kidney monitoring, especially if you have pre-existing issues. Report persistent abdominal pain or dark urine immediately.

• Storage: Store capsules at room temperature, away from moisture; keep in original packaging.

Orlistat works best with controlled fat intake; high-fat foods amplify side effects without boosting weight loss.

• High-Fat Meals (High): Avoid meals with >30% fat calories, as they cause excessive oily discharge, gas, and urgency. Spread fats evenly across meals.

• Alcohol (Low): Moderate use is generally fine, but excess can worsen GI upset; no direct interaction noted.

• Fatty Foods (High): Walnuts, oils, or fried items trigger stronger malabsorption effects—opt for grilled/steamed preparations.

Orlistat primarily impacts fat-soluble drugs via reduced absorption.

• Fat-Soluble Vitamins (High): Separate dosing by 2+ hours; routine supplementation advised.

• Cyclosporine/Warfarin (Moderate): Monitor levels closely; absorption interference possible.

• Antidiabetics/Thyroid Hormones (Moderate): Dose adjustments may be needed for glycemic or thyroid control.

• Acarbose (Low): Possible additive GI effects; monitor tolerance.

Orlistat affects fat absorption, so caution is required in conditions involving digestion or nutrient uptake.

• Chronic Malabsorption Syndrome (High): Contraindicated; worsens nutrient deficiencies.

• Kidney Stones/Oxalate Hyperabsorption (High): Risk of oxalate nephropathy—stay hydrated and monitor urine output.

• Gallbladder Issues/Cholestasis (High): May exacerbate; avoid in acute cases.

• Liver Disease (Moderate): Use cautiously with monitoring; rare hepatitis reports.

• Hypothyroidism/Diabetes (Moderate): May alter glycemic control—adjust antidiabetic meds as needed.

If you miss a dose, skip it entirely—do not take it later or double up. Only take with fat-containing meals; if the meal was missed or fat-free, no dose is needed. Restart with your next main meal as scheduled. Missing occasional doses has minimal impact if overall adherence is good, but consistent use is key for sustained weight management.